Anaptysbio Inc Financials
Anaptysbio Inc (ANAB) reported $234.6M in revenue for fiscal year 2025, up 157.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AnaptysBio’s FY2025 rebound came from episodic revenue finally outrunning research spend, while the equity cushion stayed thin.
The most telling shift is that the reported debt-to-equity ratio climbed to 8.8x in FY2025 even though total liabilities fell to$327.2M from$413.0M in FY2024. That combination means the balance sheet looks more levered mainly because the book equity cushion shrank to$37.2M , not because new debt visibly replaced the 2024 cash burn.
FY2025 operating income of
The earnings swing was driven more by revenue scale than by austerity: revenue jumped to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Anaptysbio Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Anaptysbio Inc scores 2.21, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.7B) relative to total liabilities ($327.2M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Anaptysbio Inc passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Anaptysbio Inc reported a net loss of $13.2M while generating $19.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Anaptysbio Inc generated $234.6M in revenue in fiscal year 2025. This represents an increase of 157.0% from the prior year.
Anaptysbio Inc's EBITDA was $48.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 142.4% from the prior year.
Anaptysbio Inc reported -$13.2M in net income in fiscal year 2025. This represents an increase of 90.9% from the prior year.
Anaptysbio Inc earned -$0.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 91.0% from the prior year.
Cash & Balance Sheet
Anaptysbio Inc generated $19.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 114.5% from the prior year.
Anaptysbio Inc held $238.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Anaptysbio Inc's operating margin was 20.4% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Anaptysbio Inc's net profit margin was -5.6% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Anaptysbio Inc's ROE was -35.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 169.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Anaptysbio Inc invested $136.0M in research and development in fiscal year 2025. This represents a decrease of 17.0% from the prior year.
Anaptysbio Inc spent $68.6M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 14949.6% from the prior year.
Anaptysbio Inc invested $87K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 75.7% from the prior year.
ANAB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $232.4M | $234.6M+157.0% | $91.3M+432.0% | $17.2M+66.8% | $10.3M-83.7% | $63.2M-15.8% | $75.0M+837.5% | $8.0M+60.0% | $5.0M-50.0% | $10.0M-40.1% | $16.7M-5.0% | $17.6M |
| R&D Expenses | $128.8M | $136.0M-17.0% | $163.8M+23.9% | $132.3M+49.0% | $88.8M-9.8% | $98.5M+23.1% | $80.0M-19.4% | $99.3M+76.8% | $56.2M+90.9% | $29.4M+91.0% | $15.4M-10.9% | $17.3M |
| SG&A Expenses | $62.8M | $50.7M+19.7% | $42.4M+1.1% | $41.9M+14.5% | $36.6M+70.5% | $21.5M+14.0% | $18.9M+17.1% | $16.1M+3.7% | $15.5M+66.3% | $9.3M+117.7% | $4.3M+19.5% | $3.6M |
| Operating Income | $40.8M | $47.9M+141.7% | -$114.9M+30.1% | -$164.4M-42.8% | -$115.2M-102.7% | -$56.8M-137.9% | -$23.9M+77.8% | -$107.4M-61.0% | -$66.7M-131.8% | -$28.8M-851.4% | -$3.0M+8.9% | -$3.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $1.0M-37.0% | $1.7M-6.9% | $1.8M+287.6% | $458K-0.4% | $460K |
| Income Tax | $160K | $164K+5366.7% | $3K+175.0% | -$4K-116.7% | $24K | $0 | $0+100.0% | -$152K+20.8% | -$192K | $0 | $0-100.0% | $139K |
| Net Income | -$26.8M | -$13.2M+90.9% | -$145.2M+11.2% | -$163.6M-27.1% | -$128.7M-122.7% | -$57.8M-190.0% | -$19.9M+79.5% | -$97.3M-57.9% | -$61.7M-105.0% | -$30.1M-606.0% | -$4.3M+21.2% | -$5.4M |
| EPS (Diluted) | — | -$0.46+91.0% | -$5.12+15.8% | -$6.08-33.0% | -$4.57-116.6% | -$2.11-189.0% | -$0.73+79.7% | -$3.60-44.0% | -$2.50-64.5% | -$1.52 | -$1.62 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ANAB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $364.4M-24.7% | $483.8M+7.0% | $452.4M-25.9% | $610.4M-5.1% | $643.1M+54.4% | $416.6M-4.3% | $435.2M-14.5% | $509.0M+54.5% | $329.4M+429.7% | $62.2M | N/A |
| Current Assets | $350.3M-18.9% | $431.9M+6.2% | $406.8M-9.0% | $447.2M-19.3% | $553.9M+39.7% | $396.6M+5.0% | $377.7M-13.0% | $434.2M+71.8% | $252.7M+334.1% | $58.2M | N/A |
| Cash & Equivalents | $238.2M+93.5% | $123.1M+242.2% | $36.0M-49.6% | $71.3M-85.6% | $495.7M+97.9% | $250.5M+46.5% | $171.0M+50.5% | $113.6M+39.9% | $81.2M+58.5% | $51.2M-1.0% | $51.7M |
| Total Liabilities | $327.2M-20.8% | $413.0M+13.4% | $364.3M+4.6% | $348.3M+21.5% | $286.6M+1346.2% | $19.8M-34.3% | $30.2M+33.4% | $22.6M+3.9% | $21.8M-78.3% | $100.4M | N/A |
| Current Liabilities | $38.6M-15.0% | $45.4M+21.3% | $37.4M+43.7% | $26.1M+61.8% | $16.1M-18.8% | $19.8M-32.9% | $29.5M+35.3% | $21.8M+55.0% | $14.1M+146.8% | $5.7M | N/A |
| Total Equity | $37.2M-47.5% | $70.9M-19.6% | $88.1M-66.4% | $262.1M-26.5% | $356.4M-10.2% | $396.7M-2.0% | $405.0M-16.7% | $486.4M+58.1% | $307.6M+904.2% | -$38.2M-8.7% | -$35.2M |
| Retained Earnings | -$772.6M-1.7% | -$759.3M-23.6% | -$614.1M-36.3% | -$450.5M-40.0% | -$321.8M-21.9% | -$264.0M-8.2% | -$244.0M-66.4% | -$146.7M-72.5% | -$85.0M-54.8% | -$54.9M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ANAB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.5M | $19.7M+114.6% | -$135.3M-12.0% | -$120.8M-64.1% | -$73.6M-60.3% | -$45.9M-224.4% | -$14.2M+79.6% | -$69.5M-43.3% | -$48.5M-149.5% | -$19.4M-115.3% | -$9.0M+6.8% | -$9.7M |
| Capital Expenditures | $69K | $87K-75.7% | $358K-55.6% | $807K+125.4% | $358K-73.8% | $1.4M+140.1% | $569K-29.3% | $805K-24.3% | $1.1M+266.6% | $290K+480.0% | $50K-79.0% | $238K |
| Free Cash Flow | $4.4M | $19.6M+114.5% | -$135.7M-11.6% | -$121.6M-64.4% | -$74.0M-56.4% | -$47.3M-221.1% | -$14.7M+79.1% | -$70.3M-41.9% | -$49.6M-151.3% | -$19.7M-117.3% | -$9.1M+8.6% | -$9.9M |
| Investing Cash Flow | $248.2M | $228.0M+139.0% | $95.4M-34.1% | $144.8M+136.7% | -$394.8M-1116.7% | $38.8M-58.9% | $94.5M-28.1% | $131.4M+192.3% | -$142.5M+41.4% | -$243.1M-486016.0% | -$50K+79.0% | -$238K |
| Financing Cash Flow | -$102.8M | -$132.6M-204.4% | $127.1M+314.3% | -$59.3M-234.7% | $44.0M-82.6% | $252.3M+28802.8% | -$879K+80.4% | -$4.5M-102.0% | $223.4M-23.6% | $292.5M+3289.6% | $8.6M-78.1% | $39.4M |
| Share Buybacks | $64.2M | $68.6M+14949.6% | $456K-99.1% | $50.0M | $0 | $0 | N/A | N/A | $0 | $0-100.0% | $1K | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ANAB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.4% | -125.9% | -958.3% | -1119.4% | -89.9%-58.1pp | -31.8% | -1342.9% | -1334.4% | -287.8% | -18.1%+0.8pp | -18.9% |
| Net Margin | -5.6% | -159.1% | -953.7% | -1251.3% | -91.5%-64.9pp | -26.6% | -1216.7% | -1233.1% | -300.7% | -25.5%+5.2pp | -30.8% |
| Return on Equity | -35.6%+169.4pp | -204.9%-19.2pp | -185.7%-136.6pp | -49.1%-32.9pp | -16.2%-11.2pp | -5.0%+19.0pp | -24.0%-11.4pp | -12.7%-2.9pp | -9.8% | N/A | N/A |
| Return on Assets | -3.6%+26.4pp | -30.0%+6.2pp | -36.2%-15.1pp | -21.1%-12.1pp | -9.0%-4.2pp | -4.8%+17.6pp | -22.4%-10.3pp | -12.1%-3.0pp | -9.1%-2.3pp | -6.9% | N/A |
| Current Ratio | 9.07-0.4x | 9.51-1.4x | 10.87-6.3x | 17.16-17.2x | 34.40+14.4x | 20.01+7.2x | 12.79-7.1x | 19.89+2.0x | 17.93+7.7x | 10.20 | N/A |
| Debt-to-Equity | 8.79+3.0x | 5.83+1.7x | 4.13+2.8x | 1.33+0.5x | 0.80+0.8x | 0.050.0x | 0.070.0x | 0.050.0x | 0.07 | N/A | N/A |
| FCF Margin | 8.4% | -148.7% | -708.8% | -718.9% | -74.9%-55.2pp | -19.6% | -879.0% | -991.4% | -197.3% | -54.4%+2.1pp | -56.5% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Anaptysbio Inc Ranks
Frequently Asked Questions
What is Anaptysbio Inc's annual revenue?
Anaptysbio Inc (ANAB) reported $234.6M in total revenue for fiscal year 2025. This represents a 157.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Anaptysbio Inc's revenue growing?
Anaptysbio Inc (ANAB) revenue grew by 157.0% year-over-year, from $91.3M to $234.6M in fiscal year 2025.
Is Anaptysbio Inc profitable?
No, Anaptysbio Inc (ANAB) reported a net income of -$13.2M in fiscal year 2025, with a net profit margin of -5.6%.
What is Anaptysbio Inc's EBITDA?
Anaptysbio Inc (ANAB) had EBITDA of $48.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Anaptysbio Inc's operating margin?
Anaptysbio Inc (ANAB) had an operating margin of 20.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Anaptysbio Inc's net profit margin?
Anaptysbio Inc (ANAB) had a net profit margin of -5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Anaptysbio Inc's return on equity (ROE)?
Anaptysbio Inc (ANAB) has a return on equity of -35.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Anaptysbio Inc's free cash flow?
Anaptysbio Inc (ANAB) generated $19.6M in free cash flow during fiscal year 2025. This represents a 114.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Anaptysbio Inc's operating cash flow?
Anaptysbio Inc (ANAB) generated $19.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Anaptysbio Inc's total assets?
Anaptysbio Inc (ANAB) had $364.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Anaptysbio Inc's capital expenditures?
Anaptysbio Inc (ANAB) invested $87K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Anaptysbio Inc spend on research and development?
Anaptysbio Inc (ANAB) invested $136.0M in research and development during fiscal year 2025.
What is Anaptysbio Inc's current ratio?
Anaptysbio Inc (ANAB) had a current ratio of 9.07 as of fiscal year 2025, which is generally considered healthy.
What is Anaptysbio Inc's debt-to-equity ratio?
Anaptysbio Inc (ANAB) had a debt-to-equity ratio of 8.79 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Anaptysbio Inc's return on assets (ROA)?
Anaptysbio Inc (ANAB) had a return on assets of -3.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Anaptysbio Inc's Altman Z-Score?
Anaptysbio Inc (ANAB) has an Altman Z-Score of 2.21, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Anaptysbio Inc's Piotroski F-Score?
Anaptysbio Inc (ANAB) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Anaptysbio Inc's earnings high quality?
Anaptysbio Inc (ANAB) reported a net loss of $13.2M while generating $19.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Anaptysbio Inc?
Anaptysbio Inc (ANAB) scores 82 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.